InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: INM
TL;DR
INMED filed an 8-K on Nov 19th, check it for Reg FD and financials.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on November 19, 2025, reporting an event on November 18, 2025. The filing indicates a Regulation FD Disclosure and includes Financial Statements and Exhibits. The company is incorporated in British Columbia and its principal executive offices are located in Vancouver, Canada.
Why It Matters
This 8-K filing signals important disclosures or events from InMed Pharmaceuticals, potentially impacting investors' understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for disclosures and exhibits, not indicating immediate significant financial or operational changes.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- November 18, 2025 (date) — Earliest event reported
- November 19, 2025 (date) — Date of report
- Vancouver, B.C. Canada (location) — Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing indicates a Regulation FD Disclosure and includes Financial Statements and Exhibits, but the specific triggering event is not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on November 18, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada V6C 3E8.
What is the company's telephone number?
The company's telephone number, including area code, is (604) 669-7207.
What is the company's fiscal year end?
The company's fiscal year end is June 30.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-11-19 16:28:02
Filing Documents
- ea0266453-8k_inmed.htm (8-K) — 26KB
- ea026645301ex99-1_inmed.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-25-112644.txt ( ) — 229KB
- inm-20251118.xsd (EX-101.SCH) — 3KB
- inm-20251118_lab.xml (EX-101.LAB) — 33KB
- inm-20251118_pre.xml (EX-101.PRE) — 22KB
- ea0266453-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 18, 2025, the Company announced the successful completion of pharmacokinetic ("PK") studies in large animal models for its Alzheimer's disease candidate INM-901. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated November 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: November 19, 2025 By: /s/ Eric A Adams Eric A Adams President & CEO 2